PubMed Journals Articles About "Latanoprost Xalatan Ocular Hypertension" 
Latanoprost Xalatan Ocular Hypertension PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Latanoprost Xalatan Ocular Hypertension articles that have been published worldwide.
More Information about "Latanoprost Xalatan Ocular Hypertension" on BioPortfolio
We have published hundreds of Latanoprost Xalatan Ocular Hypertension news stories on BioPortfolio along with dozens of Latanoprost Xalatan Ocular Hypertension Clinical Trials and PubMed Articles about Latanoprost Xalatan Ocular Hypertension for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Latanoprost Xalatan Ocular Hypertension Companies in our database. You can also find out about relevant Latanoprost Xalatan Ocular Hypertension Drugs and Medications on this site too.
Showing "latanoprost Xalatan Ocular Hypertension" PubMed Articles 1–25 of 7,200+
A review of the use of latanoprost for glaucoma since its launch.
Introduction: Prostaglandins are increasingly used as first choice treatment for glaucoma because they are highly effective, lack relevant systemic side effects and require just once-daily administration. Latanoprost is an ester prodrug analog of prostaglandin F2α, which reduces intraocular pressure (IOP) by increasing uveoscleral outflow. Latanoprost 0.005% has received European and US approval as the first-line drug for reducing IOP in patients with open-angle glaucoma or ocular hypertension. Following t...
The intraocular pressure reducing effect of brinzolamide as adjunctive therapy to latanoprost.
Abstract Aim: To determine the intraocular pressure (IOP) lowering effect of brinzolamide when added to latanoprost. Materials and methods: Patients who were simultaneously on brinzolamide and latanoprost were identified from the large prospective database of patients diagnosed with primary open angle glaucoma, normal tension glaucoma or ocular hypertension maintained in our glaucoma clinic. Only patients who had been on latanoprost for at least six weeks before introduction of brinzolamide were included. T...
ABSTRACT: BACKGROUND: A noninferiority trial was conducted to evaluate the efficacy of a single evening dose of fixed-combination latanoprost 50 mug/mL and timolol 0.5 mg/mL (Xalacom(R); LTFC), in Chinese patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH) who were insufficiently controlled on beta-blocker monotherapy or beta-blocker-based dual therapy. METHODS: This 8-week, randomized, open-label, parallel-group, noninferiority study compared once-daily evening dosing of LTFC with...
PURPOSE: To prospectively assess the efficacy of switching to a travoprost/timolol fixed-combination (TTFC) therapy from latanoprost monotherapy. METHODS: This was a prospective, open-label study in which patients with either primary open-angle glaucoma or ocular hypertension who had been undergoing latanoprost monotherapy for at least 3 months were enrolled. Baseline was defined as the time when the subjects were started on latanoprost monotherapy. Examination periods were defined as 1, 2, and 3 months t...
Abstract. Purpose: To determine the cost-effectiveness of ocular hypertension (OH) treatment initiated with latanoprost compared to timolol. Methods: Two strategies for OH therapy are modelled, (1) 'starting with timolol' and (2) 'starting with latanoprost'. Therapy can be maintained or changed dependent on the achieved intraocular pressure (IOP) and side-effects. Adjustments of therapy to reach a target pressure involve monotherapy, combination therapy and laser. Four drugs are used: latanoprost, timolol,...
ABSTRACT: BACKGROUND: Prospective, observational studies that enroll large numbers of patients with few exclusion criteria may better reflect actual ongoing clinical experience than randomized clinical trials. Our purpose was to obtain efficacy and safety information from a cohort of subjects exposed to latanoprost/timolol fixed combination (FC) for [greater than or equal to]18 months using a prospective, observational design. METHODS: In all, 577 office-based ophthalmologists in Germany switched 2339 patie...
Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost.
PURPOSE: To confirm the possible mechanism by which topical prostaglandin antiglaucoma drugs cause a deep superior sulcus. METHODS: Among patients who used bimatoprost (Lumigan), latanoprost (Xalatan), or travoprost (Travatan) and who developed a deep upper lid sulcus, 18 eyes of 11 patients (mean age, 58.2 ± 8.9 years) were studied. Seven patients were binocular users of one of the eye drops and four were monocular users. Preaponeurotic orbital fat was obtained, and the mean adipocyte density compared. Re...
The stabilization mechanism of latanoprost.
The content of latanoprost is likely to decrease in solution because of the adsorption to eye drop containers and hydrolysis. We reduced these problems and established a formulation of latanoprost eye drops which is stable at room temperature. We assume that the additive surfactants form micelles and stabilize latanoprost in this formulation. In this study, we elucidated the latanoprost stabilization mechanism. It was revealed by Arrhenius analysis that the adsorption to eye drop containers and hydrolysis o...
PURPOSE: To compare the intraocular pressure (IOP) reduction over 24 h achieved with tafluprost (0.0015%) with that achieved with latanoprost (0.005%). METHODS: Twenty-seven healthy volunteers were studied. After a 24-h IOP baseline measurement was taken, one ophthalmic solution was applied to the right eye daily for 7 days. The drug was then withdrawn for 2 weeks. The other agent was then applied to the left eye in the same manner. IOP was measured every 3 h for 24 h on the seventh day of treatment. RESULT...
Objective-To determine effects after topical administration of latanoprost, timolol, or a commercially available latanoprosttimolol combination twice daily on intraocular pressure (IOP), pupil size (PS), and heart rate (HR) in clinically normal dogs. Animals-17 clinically normal dogs. Procedures-A randomized controlled clinical trial was performed with a treatment (n = 9) and saline (0.9% NaCl) solution group (8). Each dog in the treatment group received 3 treatments (latanoprost, timolol, and the latanopro...
Increased Intraocular Pressure in Mice Treated with Dexamethasone.
Purpose. Glucocorticoids are potent modulators of the immune system and are useful in treating systemic and ocular diseases, but can increase intraocular pressure (IOP) in susceptible individuals. Steroid-induced ocular hypertension resembles several characteristics observed in primary open angle glaucoma (POAG). Elucidating genetic and environmental mechanisms impacting steroid-induced ocular hypertension may provide important insight into pathophysiological drivers of POAG. The purpose of this study was t...
PURPOSE: To compare the ocular hypotensive effect of bimatoprost plus timolol and travoprost plus timolol fixed combinations in glaucoma patients whose disease was controlled but had not reached their target intraocular pressure (IOP) with the fixed combination of latanoprost plus timolol. DESIGN: A 2 x 3-month, multicenter, prospective, randomized, double-masked, cross-over clinical trial. METHODS: Eighty-nine open-angle glaucoma (OAG) patients were included. After a 6-week run-in period with latanoprost p...
Sustained ocular hypertension following intravitreal injections of 0.5 mg/0.05 ml ranibizumab.
To report three cases with sustained ocular hypertension following intravitreal injections of 0.5 mg/0.05 ml ranibizumab and to underline the importance of monitoring intraocular pressure (IOP) following intravitreal injections of ranibizumab (Lucentis). Three patients were found to have high IOP after intravitreal injections of 0.5 mg/0.05 ml ranibizumab. IOP was elevated after the second ranibizumab injection in patients 1 and 2, and after the third injection in patient 3. The increase in IOP was sust...
Comparison of efficacy of four prostaglandin analogues by bilateral treatment in healthy subjects.
PURPOSE: To compare the drug efficacy of four prostaglandin analogues (PGAs) by bilateral treatment in normal subjects. METHODS: Three consecutive studies comparing latanoprost to three other PGAs (travoprost, tafluprost and bimatoprost) were performed in 24 healthy subjects. Each study was separated by a washout period of over 6 weeks. In each study, two drugs were randomly assigned to one eye of each subject. Study subjects instilled the assigned medication at 9:00 p.m. every day for 2 weeks. The same...
Duration of anesthesia affects intraocular pressure, but not outflow facility in mice.
Purpose: The study of aqueous humor dynamics (AHD) in mice is becoming more prevalent as more strains with elevated intraocular pressure (IOP) are developed. High IOP is usually associated with reduced outflow facility making this one of the more important AHD parameters to evaluate. Ocular measurements in mice require anesthesia that has profound effects on IOP but unknown effects on outflow facility. This study evaluates the effects of anesthesia duration and latanoprost treatment on outflow facility and...
Abstract Purpose: To evaluate secondary ocular hypertension after intravitreal injection of triamcinolone acetonide (IVTA) with 2 mg/0.05 mL or 4 mg/0.1 mL for macular edema associated with retinal vein occlusion (RVO). Methods: A retrospective chart review was performed. Patients with RVO, including central RVO and branch RVO, were divided into 2 groups. Group 1 was patients who received 2 mg IVTA and group 2 received 4 mg IVTA. The dose of IVTA was dependent on individual surgeon's decision. Secondary ocu...
Increased intraocular pressure is the main cause of glaucoma development. However, the systemic information of genes related to ocular hypertension has not yet been clarified. In the present study, oligomicroarray determined the profile of gene expression in the retina after ocular hypertension. A rat ocular hypertension model was constructed through photocoagulation by diode lasers. On postoperative days 7, 35, 60, 90, 180 and 360, the intraocular pressure and the gene expression profile were determined us...
Spontaneous hyphaema and acute ocular hypertension associated with severe lens-induced uveitis.
PurposeTo report the occurrence of spontaneous hyphaema and acute ocular hypertension in four patients with severe lens-induced anterior uveitis.MethodsRetrospective case series.ResultsFour patients with mature cataract developed severe acute, unilateral, anterior uveitis associated with spontaneous hyphaema formation and acutely elevated intraocular pressure. None of the patients had a history of trauma or evidence of angle, iris, or retinal neovascularization. Prompt cataract removal led to resolution of...
To assess the impact of 2 strategies for initiating therapy in ocular hypertension (OH) on drug use, intraocular pressure (IOP), and blindness caused by glaucoma.
BACKGROUND: In the setting of head trauma, progressive bradycardia may raise suspicion for intracranial hypertension, especially when accompanied by pupillary abnormalities or systemic hypertension. METHODS: We describe the case of a patient with concomitant cerebral and ocular trauma who presented with a fixed and dilated pupil and progressive bradycardia due to an oculocardiac reflex. RESULTS: The oculocardiac reflex is an unusual cause of bradycardia due to stimulation of the ophthalmic division of the t...
Ocular and Orbital Pain for the Headache Specialist.
Ocular pain is most commonly associated with redness and inflammation; however, eye pain can also occur in the absence of grossly visible pathology. Pain in the quiet eye can be the first sign of a number of threatening conditions. Many of these conditions such as intermittent angle closure glaucoma, carotid artery dissection, idiopathic intracranial hypertension, and giant cell arteritis can lead to permanent vision loss or blindness. In this review, ocular history and examination techniques are summarized...
Adverse periocular reactions to five types of prostaglandin analogs.
PurposeWe investigated the appearance frequency of eyelid pigmentation and eyelash bristles after the use of five types of prostaglandin (PG) analogs.MethodsThis study included 250 eyes from 250 patients diagnosed with primary open-angle glaucoma or ocular hypertension who were treated with either latanoprost, travoprost, tafluprost, bimatoprost, or isopropyl unoprostone for >3 months in only one eye. Photographs of both eyes were obtained, and the images were assessed by three ophthalmologists who were mas...
Purpose: Amyloid precursor protein (APP) and amyloid-beta (Abeta) appear to participate in the pathophysiology of retinal ganglion cell (RGC) death in glaucoma. We, therefore, determined the distribution of APP and Abeta in the retinas of C57BL/6 mice after induction of chronic ocular hypertension. Methods: Ocular hypertension was induced in one eye of three-month-old C57BL/6 mice by injection of hypertonic saline into episcleral veins. After 6 weeks of documented elevated intraocular pressure (IOP), retina...
Etiology of ocular diseases in elderly Amis aborigines in Eastern Taiwan (The Amis Eye Study).
PURPOSE: To determine the incidence of and risk factors associated with major ocular diseases in the elderly Amis population of Taiwan. METHODS: This population-based cross-sectional study is the most current survey of ocular diseases among elderly Amis. The overall response rate was 61.2%, with 2316 participants screened. All ocular examinations were performed using a mobile ophthalmology setup staffed by an ophthalmologist with 30 years of experience. RESULTS: The mean age of the participants was 71.65 ye...
Incidence of deepening of the upper eyelid sulcus after switching from latanoprost to bimatoprost.
PURPOSE: To investigate the incidence of deepening of the upper eyelid sulcus (DUES) after use of bimatoprost in Japanese glaucoma patients. METHODS: Twenty-five open-angle glaucoma Japanese patients treated with latanoprost in both eyes for 6 months or longer and needing further intraocular pressure (IOP) reduction were enrolled prospectively. Latanoprost was switched to bimatoprost, and the patients were observed at 1, 3,...
